Presented by expert speakers from leading pharmaceutical companies, these workshops will give you advanced insights into topic areas that the event will address

Can’t make the date? Still register to receive the recording afterwards.

Peptides Webinars

Proteins & Antibodies Digital Workshops

Targeted, Controlled and Responsive Therapeutic Delivery through the Design of Self-Assembling Peptide Hydrogels

Tuesday 14th January 2020 | 2PM GMT

Presented by Aline Miller, Professor, University of Manchester

  • Design rules for engineering responsive peptide hydrogels
  • Targeting endometriosis with sprayable peptide hydrogels
  • Delivery of therapeutics to solid tumours
  • Mucoadhesive hydrogels to prolong therapeutic efficacy

Aline Miller, PhD, is a Professor of Biomolecular Engineering in the School of Chemical Engineering at the University of Manchester where she has won several awards, including The Royal Society of Chemistry MacroGroup UK Young Researchers Medal, The Institute of Physics, Polymer Physics Group Young Researchers Lecture Award and the Philip Leverhulme Prize for Engineering for her work on self-assembling peptide materials. In this area she has published over 100 refereed papers, authored 5 patents and has won > £8M from research councils, EU, charities and industry to support her research group. Aline is also Chief Executive Officer and Co-Founder of Manchester BIOGEL, a company specialising in providing engineered, self-assembling peptide hydrogels for 3D cell culture, 3D bioprinting and incorporation within medical devices. She currently oversees all aspects of the business from product production and development, to marketing and sales, to ensure our customers receive the very best product and service.

Our free webinar is for peptide professionals based in the UK, EU and US interested in learning more about the opportunities and challenges that exist within peptide targeted therapeutic delivery. This is a free event open to all, so why not register and benefit from the expertise of our speakers.

BIOANALYSIS | 9th June

The Impact Of Proline isomerization On Antigen Binding And The Analytical Profile Of A Trispecific Anti-HIV Antibody

Tuesday 9th June 2020 | 16:00 - 16:25 BST

ALESSANDRO MASIERO, Research Scientist, Sanofi

  • Aberrant size exclusion chromatography (SEC) profile and pH dependance
  • Structural and molecular dynamics analyses
  • Correlation of in silico/in vitro data and validation

Antibody Screening Cascades: A Case Study For Biotherapeutic Discovery

Tuesday 9th June 2020 | 16:25 - 16:50 BST

KELLY LOYET, Senior Scientist, Genentech

  • Following target identification for therapeutic development, it is important to assemble a relevant suite of functional assays amenable to screening from hundreds to thousands of antibodies and subsequent confirmation of hits
  • These assays balance high-throughput nature for rapid screening and recapitulation of physiological aspects for best translatability of the lead
  • Here I will present a biotherapeutic antibody discovery case study and future perspectives for developing the best functional assays to fit the project needs

iBEACON As An Analytical And Formulation Development Tool For Assessing Biologics Developability

Tuesday 9th June 2020 | 16:50 - 17:15 BST

RAMESH IYER, Principal Research Scientist, AbbVie

  • Developability assessment of a biologic is critical to ensure a drug candidate can be developed into a therapeutic
  • The process requires assessment of physicochemical properties and formulation development of candidates typically at high concentrations
  • We describe an instrument developed at AbbVie called iBEACON that enables screening candidates from a typical drug discovery process at higher throughput
  • The presentation will cover the design of iBEACON and type of data that can be collected to drive decision-making

Analytical Analysis Of Bispecific Antibodies From The Protein Folding Point Of View

Tuesday 9th June 2020 | 17:15 - 17:40 BST

MARK CHIU, Head of Process Analytical Support for Analytical Resource Team, Janssen

Beyond Binding Kinetics: “Rmax-imizing” SPR In Biopharmaceutical Discovery

Tuesday 9th June 2020 | 17:40 - 18:10 BST

ENRICO DIGIAMMARINO, Principal Research Scientist, AbbVie

We have implemented an often underutilized SPR measure to characterize the function and quality of biological therapeutics: binding stoichiometry. Examples will be discussed showing how it can be used to demonstrate function of biotherapeutic candidates as well as reveal novel binding modes, identify signs of molecular liabilities and aid in engineering functional biotherapeutic molecules.

Peptides Digital Workshops

PEPTIDE THERAPEUTICS | 12th June

Accelerated Forced Degradation Of Therapeutic Peptides In Levitated Microdroplets

Friday 12th June 2020 | 14:00 - 14:25 BST

YONG LIU, Senior Principal Scientist, Merck

  • A new method was developed to study, over the course of seconds, peptide degradation in levitated aqueous microdroplets on a metal dice using the Leidenfrost effect
  • This two-minute reaction and analysis by mass spectrometry workflow was demonstrated through the study of major peptide degradation pathways include deamidation, disulfide bond cleavage, ether cleavage, hydrolysis, and oxidation
  • This work can be applied to rapidly determine the intrinsic stability of therapeutic peptides and to aid formulation development

Considerations for the Developability of Peptides for Parenteral Delivery

Friday 12th June 2020 | 14:25 - 14:50 BST

Presented by MARIANNA YANEZ ARTETA, Senior Scientist Formulation/Physical Chemistry, AstraZeneca

  • Parenteral delivery of peptides, albeit being the most common route of administration, has many challenges for formulation development, such as poor solubility and lack of physical and chemical stability.
  • The design of a formulation screening strategy for parenteral delivery of peptides will be outlined, which is key for the success of projects.
  • Formulation approaches for sustained release of peptides, which allow less frequent dossing, will be as well discussed.

Marianna Yanez Arteta is an experienced Physical Chemist that presently holds a Senior Scientist Formulator position in the Advanced Drug Delivery division within Pharmaceutical Science at AstraZeneca in Gothenburg, Sweden. In her role, she is technical lead in the development of formulations for new modalities pharmaceutics, including peptides, messenger RNA and oligonucleotides. She brings her expertise in scattering techniques to the screening of peptide formulations in pre-clinical development.

She has a Chemistry degree from Simón Bolívar University in Caracas, Venezuela (2010) and a PhD degree in Physical Chemistry from Lund University in Lund, Sweden (2014). She did her postdoc research at AstraZeneca, where she investigated the structure of lipid nanoparticles to improve their efficacy as gene delivery vehicles. Currently, she manages scientific collaborations with academia in this field. Besides scattering, her areas of expertise are surface and colloidal chemistry and surface techniques (e.g. neutron reflectivity, ellipsometry, quartz crystal microbalance)

Bispecifics Digital Workshops

BISPECIFICS: DISCOVERY & PLATFORM DEVELOPMENT | 2nd July

Using CrossMab Technology For Development Of Bispecific Antibodies

Thursday 2nd July 2020 | 14:00 - 14:25 BST

CHRISTIAN KLEIN, Department Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich

  • Basis of CrossMab technology
  • Engineering features of CrossMabs and application of CrossMab technology for generation of diverse set of bispecific antibody formats
  • CrossMabs in development incuding antiangiogenesis, checkpoint inhibition, T cell bispecific antibodies and antibody fusion proteins
  • Examples of CrossMabs in academic research

Bispecific ADCs Targeting HER2: Intracellular Traffi cking Of The Antibody Dictates The Choice Of Linker-Payload

Thursday 2nd July 2020 | 14:25 - 14:50 BST

JULIAN ANDREEV, Research Fellow, Regeneron

Bispecific ADCs bridging HER2 and high turnover proteins travel to lysosomes and improve effi cacy of HER2 ADCs with non-cleavable linker-DM1. Biparatopic HER2 ADCs induce target internalization and require cleavable linker for greater efficacy. Combining various bispecific antibody approaches with correct linker-payload technology may allow to generate ADCs with better efficacy and safety profiles.

Fusions And DutaFabs: An Update On Roche’s Bispecific Platforms

Thursday 2nd July 2020 | 14:50 - 15:15 BST

MARLON HINNER, Principal Scientist & Group Leader, Roche Innovation Centre Munich

Targeting Bispecifics

Thursday 2nd July 2020 | 15:15 - 15:40 BST

DANIELLE MANDIKIAN, Scientist, Genentech

Looking for more?

All of our past webinars are available for download from our Content HUB, as well as Market Industry Reports, Q&A Sessions, Newsletters and much more.